Non-clinical Evaluation of 4D-310 in Combination With Rituximab/Sirolimus: A Translational Study to Support Adoption of a Novel Prophylactic Immunomodulation Regimen in Clinical Trials in Adults with Fabry Disease

Phase 1/2 Clinical Trial Evaluating 4d-310 In Adults With Fabry Disease Cardiomyopathy: Interim Analysis of Cardiac and Safety Outcomes in Patients with 21-42 Months of Follow Up (Poster)

Phase 1/2 Clinical Trial Evaluating 4d-310 In Adults With Fabry Disease Cardiomyopathy: Interim Analysis of Cardiac and Safety Outcomes in Patients with 21-42 Months of Follow Up

Non-clinical Evaluation of 4D-310 in Combination With Rituximab/Sirolimus: A Translational Study to Support Adoption of a Novel Prophylactic Immunomodulation Regimen in Clinical Trials in Adults with Fabry Disease (Poster)

24-week Results from the Randomized Phase 2 Dose Expansion Stage of the PRISM Trial Evaluating 4D-150 in High Need nAMD Patients: Injection-free Patient Analyses

CFTR Transgene Expression in Airway Epithelial Cells Following Aerosolized Administration of the AAV-based Gene Therapy 4D-710 to Adults with Cystic Fibrosis Lung Disease